Attractin (ATRN)

Attractin (ATRN) is a multifunctional protein present in both transmembrane and secreted (soluble) forms, generated by alternative splicing from a single gene. It belongs to the CUB family of cell adhesion and guidance proteins, possessing protease activity reminiscent of DPPIV, with a domain structure including EGF-like repeats, a CUB domain, and a C-type lectin domain[2][4][1]. Transmembrane attractin plays a key role in immune cell interactions, especially during T lymphocyte activation, facilitating cell–cell clustering and monocyte activation. Soluble attractin is released into plasma after T cell activation and can modulate cytokine and chemokine activity. In mice, attractin deficiency (mahogany mutation) leads to abnormal pigmentation and energy metabolism, linking the protein to regulation of melanocortin signaling and metabolic control. In humans and rodents, ATRN also contributes to neuronal homeostasis, with loss-of-function mutations causing spongiform neurodegeneration and related neuropathology[3][5]. ATRN expression occurs widely, including in immune, nervous, and various secretory tissues, and genetic variability may impact skin cancer risk, pigmentation, and possibly neuropsychiatric phenotypes[1][3][5]. No direct drug interactions are presently listed in major databases, and no specific clinical biomarkers in use have been identified. Notable therapeutic challenges include the risk of neurodegeneration, altered pigment phenotypes, and metabolic dysregulation upon loss or modulation of function.

Other names

AttractinATRNKIAA0548DPPT-LMahogany homologMahogany proteinMGCAAttractin-2

Modulation of immune cell–cell interactions; Proteolytic modification of cytokines/chemokines; Regulation of melanocortin receptor function (indirect, via protein interactions)